article thumbnail

FDA approves first in vivo gene insertion programme in infants

Drug Discovery World

The Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for ECUR-506 makes it the first in vivo gene insertion programme authorised for clinical investigation in infants in the US. The post FDA approves first in vivo gene insertion programme in infants appeared first on Drug Discovery World (DDW).

In-Vivo 80
article thumbnail

‘In vivo’ cell therapy: expanding beyond CAR-T

Bio Pharma Dive

At least five startups have emerged with new ways to genetically modify immune cells within the body, an approach that, if successful, could widen the field of CAR-T treatment.

In-Vivo 359
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

3rd In Vivo Cell Engineering & Gene Editing Summit

pharmaphorum

Achieve Safe & Targeted In Vivo Delivery of Payloads with Clarity in Regulations & Appropriate Models to Advance the Next Frontier of In Vivo Editing from Research to Clinic

In-Vivo 52
article thumbnail

$175M financing will support development of in vivo CAR-T therapies

Drug Discovery World

The proceeds will be used to advance CPTX2309, Capstan’s lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders, and to further develop Capstan’s tLNP pipeline. Biotechnology company Capstan Therapeutics has raised $175 million in an oversubscribed Series B financing.

In-Vivo 52
article thumbnail

Astellas teams up with startup Kelonia to make ‘in vivo’ cell therapies

Bio Pharma Dive

Kelonia will receive $40 million upfront through a partnership to develop “off-the-shelf” cell therapies for cancer.

In-Vivo 291
article thumbnail

€30m raised for first-in-class in vivo cell reprogramming platform

Drug Discovery World

The therapy has achieved preclinical proof of concept (PoC) in patient-derived ex vivo models as well as rodent in vivo models, inducing strong anti-tumour immunity and abscopal effect, even in a monotherapy setting. We believe this breakthrough strategy will give rise to the next generation of cell therapies.

In-Vivo 52
article thumbnail

Capstan heats up ‘in vivo’ cell therapy chase with $175M fundraise

Bio Pharma Dive

The high-profile startup, co-founded by CAR-T innovator Carl June, will use the funds to bring an autoimmune disease treatment into proof-of-concept studies.

In-Vivo 177